I agree- BLRX looks intriguing and I will be doing further research on this one. Looks like they reacquired the rights to the lead candidate from Cypress after the Cypress activist shareholder/Royalty Pharma buyout (less than a year after signing license deal with BioLineRx)
Market Data 
Markets 
AI
